InflaRx and current shareholders placed $ 117,3 Mio. of shares, with $ 63 Mio. as primary shares with the proceeds going to InflaRx and $ 54 Mio. as secondary shares with the proceeds going to early shareholders, who all remain invested in InflaRx
The NASDAQ listed company, InflaRx NV (Nasdaq: IFRX) from Jena informed the markets of a primary and secondary share placement in total of $ 117,3 Mio. $ 63 Mio. worth of shares were sold as primary shares with the proceeds going to InflaRx and $ 54 Mio. worth of shares were sold by existing shareholders as secondary shares. All selling shareholders remain invested in InflaRx.
InflaRx develops therapies for the treatment of inflammation-related maladies, which target the complement system, a key component of the body´s natural immune system. InflaRx intends to use the proceeds from the capital raise to finance the further clinical development of its lead candidate IFX‑1, which is currently in Phase IIb.
The therapy is being trialed on patients with moderate to advanced Hidradenitis Suppurativa (HS), which is a painful and chronic inflammatory skin disease with currently limited treatment options. Furthermore, the compound is going to be tested in two phase II trials for additional auto-immune and inflammation indications.
bm|t beteiligungsmanagement Thüringen GmbH is proud to have been the lead investor in InflaRx since day one.